Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — Shareholder Meeting (November 2023)
35 slides from Bcal Diagnostics's shareholder meeting presentation, Nov 22, 2023
Slide 1: BCAL Diagnostics Annual General Meeting
BCAL Diagnostics Annual General Meeting Chairman Jayne Shaw 22 November 2023
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation (Presentation) has been prepared by BCAL The forward-looking statements are based on information available to Not An Offer Diagnostics Ltd ABN 51 142 051 223 (BCAL or the Company). BCAL as at the date of this Presentation. Circumstances may change Th
Slide 3: Order of Proceedings
Order of Proceedings Item 1 Chairman Address Item 2 Financial Statements and Reports Item 3 Resolutions Resolution 1 - Remuneration Report Resolution 2 - Re-election Director Resolution 3 - Re-election Director Resolution 4 - Ratification of issue of placement shares under 7.1 capacity Resolution 5
Slide 4: Board of Directors
Board of Directors Jayne Shaw Hon Ron Phillips AO Jonathan Trollip Dr. Merilyn Sleigh Mark Burrows AO Executive Chair Non-executive Director Independent Non-executive Independent Non-executive Independent Non-executive director Successful businesswoman, entrepreneur Health policy expert, previously
Slide 5: Key Achievements
Key Achievements 14 years of development BCAL unique own biobank of more than BCAL commenced operating in 2009. 4000 samples State-of-the-art commercial BCAL has assembled a leading laboratory commissioned and scientific and management team. operating. BREASTEST™ has been developed BREASTESTTM holds
Slide 6: Slide 6
Slide 7: BCAL's state-of-the-art lipid test BREASTEST with automated analysis
BCAL’s state-of-the-art lipid test BREASTESTTM with automated analysis BREASTEST™ At collection centre Transit At testing laboratory Plasma Erythrocytes Whole Blood Blood Pre-processing: Sample Sample Analysis: Data analysis for collectio sample spin, separate preparation: Extracts analysed breast c
Slide 8: svi K
svi K breast cancer foundation
Slide 9: Clinical Advisory Board
Clinical Advisory Board Eminent and influential Breast Clinicians form a National Key Opinion Leader & Clinical Excellence Forum to enhance trust, provide advice and win the market Dr David Prof Bruce Dr Corinne Ooi A/Prof. James Prof. Elizabeth A/Prof. Cindy Dr Samriti Sood A/Prof. Gillian Dr Sally
Slide 10: Lipid Biomarkers in Breast Cancer Diagnosis publications
Lipid Biomarkers in Breast Cancer Diagnosis publications Serum Lipidomic Profiling in Breast Cancer to Identify Screening, Diagnostic, and Prognostic Biomarkers Karima Fichtali, Amine Bititi, Adil Elghanmi,,* and Bouchra Ghazi BioResearch Open Access Volume 9.1, 2020 Triple Negative Breast Cancer De
Slide 11: eae
eae
Slide 12: BREASTEST outperforms mammography
BREASTEST™ outperforms mammography Samples analysed by BCAL in Sydney on an OrbiTrap LC/MS Samples analysed by Precion in USA on a Triple Quad LC/MS Instrument 1 Instrument 0. 9 Sydney 0. Precion Study 8 Study 0. 7 0. 353 Cancer patients 6 390 Cancer patients 0. 268 Negative 5 266 Negative patients
Slide 13: BREASTEST has strong and growing Intellectual Property Protection
BREASTEST™ has strong and growing Intellectual Property Protection Issued * Pending * In PCT/AU2023/050389 Progress Australian Provisional Oct 31, 2023 Patent Application No. 2023903491. 20 13
Slide 14: Board of Directors and Executive Team
Board of Directors “s B CA L diagnostics We have a strong and experienced leadership operational team Jayne Shaw Executive Chair ‘Successful businesswoman, entrepreneur and co-founder. Previously co-founder and owner of the Sychney Breast Cini. Hon Ron Phillips AO Non-executive Director Health polic
Slide 15: Company Metrics
Company Metrics ASX Code BDX Unlisted Options 10.3M Share Price Cash in Bank 21 November 2023 30 September 2023* $0.11 $3.6M Shares on Issue 241.2M Top 20 Shareholders 58.2% * R&D Receipt November 2023 - $3 million BC AL DI A G N OST I C S LI M I T ED 15
Slide 16: NSW Health Statewide Biobank
NSW Health Statewide Biobank • Disciplined collection of samples under strict clinical protocol. • Over 4000 samples with capability to explore lipid signatures in other cancers such as brain, lung, ovarian and colorectal. http://biobank.health.nsw.gov.au/ 9/3/2019 NSWPATH-Biobanking@health.nsw.gov.
Slide 17: Commercial objectives timeframe
Commercial objectives timeframe BC AL D I A G N O S T I C S LI MI TE D 17
Slide 18: Current and future sites recruiting to our biorepository
Current and future sites recruiting to our biorepository 1. Sydney Breast Clinic 2. Royal Prince Alfred Hospital 3. Chris O'Brien Lifehouse 4. Westmead Hospital 5. St Vincent's Hospital 9. Michigan Healthcare Darlinghurst Professionals 6. Lakeview Private 15. NorthShore, Chicago 7. Orange Health Ser
Slide 19: BREASTEST will be available at Sydney Breast Clinic
BREASTEST™ will be available at Sydney Breast Clinic end 2024
Slide 20: Order of Proceedings
Order of Proceedings Item 1 Chairman Address Item 2 Financial Statements and Reports Item 3 Resolutions Resolution 1 - Remuneration Report Resolution 2 - Re-election Director Resolution 3 - Re-election Director Resolution 4 - Ratification of issue of placement shares under 7.1 capacity Resolution 5
Slide 21: Item 2
Item 2 Consideration of Financial Statements and Reports for the year ended 30 June 2023 • According to the Corporations Act and the Company’s constitution, shareholders are not required to approve the Financial Statements and Reports. • However, I invite any questions and remind you that Aiden Evan
Slide 22: Order of Proceedings
Order of Proceedings Item 1 Chairman Address Item 2 Financial Statements and Reports Item 3 Resolutions Resolution 1 - Remuneration Report Resolution 2 - Re-election Director Resolution 3 - Re-election Director Resolution 4 - Ratification of issue of placement shares under 7.1 capacity Resolution 5
Slide 23: Resolution 1
Resolution 1 Remuneration Report • To receive and consider the Remuneration Report for the year ended 30 June 2023 in accordance with Section 250R(2) of the Corporations Act 2001 and if thought fit to pass, with or without amendment, the following Ordinary Resolution: “That for the purposes of secti
Slide 24: Resolution 2
Resolution 2 Re-election Director • To consider, and if thought fit, to pass the following as an ordinary resolution: “THAT Mr Ronald Phillips, who retires by rotation in accordance with Rule 8.6 of the Company’s constitution and Listing Rule 14.4 and, being eligible and offering himself for re-elec
Slide 25: Resolution 3
Resolution 3 Re-election Director To consider, and if thought fit, to pass the following as an ordinary resolution: “THAT Mr Mark Burrows, who retires by rotation in accordance with Rule 8.6 of the Company’s constitution and Listing Rule 14.4 and, being eligible and offering himself for re-election,
Slide 26: Resolution 4
Resolution 4 Ratification of issue placement shares under LR 7.1 capacity To consider and, if thought fit, to pass the following resolution as an ordinary resolution: • “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 23,500,000 Placement S
Slide 27: Resolution 5
Resolution 5 Approval of Director participation in placement To consider, and if thought fit, to pass the following as an ordinary resolution: “That, under and for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue: up to 200,000 Director Pl
Slide 28: Resolution 6
Resolution 6 Approval of Director participation in placement To consider, and if thought fit, to pass the following as an ordinary resolution: “That, under and for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue: up to 300,000 Director Pl
Slide 29: Resolution 7
Resolution 7 Ratification of issue shares to John Hurrell To consider, and if thought fit, to pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 200,000 Shares to CEO John Hurrell on the terms and
Slide 30: Resolution 8
Resolution 8 Ratification of issue of broker options To consider, and if thought fit, to pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 350,000 Options to PAC Partners Securities Pty Ltd, or t
Slide 31: Resolution 9
Resolution 9 Ratification of issue of broker options To consider, and if thought fit, to pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 350,000 Options to MST Financial Services Pty Ltd, or th
Slide 32: Resolution 10
Resolution 10 Ratification of issue of Advisor shares and options To consider, and if thought fit, to pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of: • 200,000 Shares; and • 334,243 Options, t
Slide 33: Resolution 11
Resolution 11 Approval of Additional 10% Placement Capacity To consider and, if thought fit, to pass the following resolution as a special resolution: "That, for the purposes of ASX Listing Rule 7.1A and all other purposes, approval is given for the Company to allot and issue Equity Securities up to
Slide 34: Questions
Questions
Slide 35: Thank You
Thank You
BCAL Diagnostics — Shareholder Meeting (November 2023) on 6ix